Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Next Previous
Trial Profile

A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema
  • Focus Adverse reactions; Proof of concept; Registrational
  • Acronyms ORION-1
  • Sponsors Aerie Pharmaceuticals

    • Most Recent Events

    • 01 Jan 2023 Results published in the Retina.
    • 04 Nov 2021 According to an Aerie Pharmaceuticals media release, topline results from this trial were presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists 2021.
    • 06 Oct 2021 According to an Aerie Pharmaceuticals media release, topline results from this trial will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top